Moreover, tumor‐associated macrophages (TAMs) suppress CD8+ T‐cell mediated immunity by fostering an immunosuppressive tumor microenvironment (TME) that shields tumor cells from immune attack.[21] As a result, the response rates of patients to neoantigen peptide vaccines are comparatively low, leading to the unsuccessful eradication of solid tumors at advanced stages. Here, CD8A is linked to neoplasm.